JP2021507707A5 - - Google Patents
Info
- Publication number
- JP2021507707A5 JP2021507707A5 JP2020534373A JP2020534373A JP2021507707A5 JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5 JP 2020534373 A JP2020534373 A JP 2020534373A JP 2020534373 A JP2020534373 A JP 2020534373A JP 2021507707 A5 JP2021507707 A5 JP 2021507707A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- mev
- acid construct
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192505A JP2024009058A (ja) | 2017-12-21 | 2023-11-10 | ラッサワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609155P | 2017-12-21 | 2017-12-21 | |
| US62/609,155 | 2017-12-21 | ||
| PCT/IB2018/001620 WO2019123018A2 (en) | 2017-12-21 | 2018-12-20 | Lassa vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192505A Division JP2024009058A (ja) | 2017-12-21 | 2023-11-10 | ラッサワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021507707A JP2021507707A (ja) | 2021-02-25 |
| JP2021507707A5 true JP2021507707A5 (enExample) | 2026-01-26 |
| JP7841847B2 JP7841847B2 (ja) | 2026-04-07 |
Family
ID=65763665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534373A Active JP7841847B2 (ja) | 2017-12-21 | 2018-12-20 | ラッサワクチン |
| JP2023192505A Pending JP2024009058A (ja) | 2017-12-21 | 2023-11-10 | ラッサワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192505A Pending JP2024009058A (ja) | 2017-12-21 | 2023-11-10 | ラッサワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11976305B2 (enExample) |
| EP (1) | EP3727411A2 (enExample) |
| JP (2) | JP7841847B2 (enExample) |
| KR (1) | KR102822230B1 (enExample) |
| CN (1) | CN111886342B (enExample) |
| AU (1) | AU2018392826B2 (enExample) |
| CA (1) | CA3085224A1 (enExample) |
| MX (1) | MX2020006476A (enExample) |
| SG (1) | SG11202004899SA (enExample) |
| WO (1) | WO2019123018A2 (enExample) |
| ZA (1) | ZA202003070B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111206022A (zh) * | 2020-02-20 | 2020-05-29 | 中国人民解放军军事科学院军事医学研究院 | 一种表达拉沙热病毒空衣壳的重组病毒及其制备方法 |
| KR102404143B1 (ko) * | 2020-04-21 | 2022-05-31 | 대한민국(질병관리청장) | 라싸 바이러스 핵단백질에 특이적인 항체, 이를 생산하는 하이브리도마 세포주 및 이를 이용한 라싸 바이러스 검출 키트 |
| TWI815572B (zh) * | 2021-09-27 | 2023-09-11 | 美商圖策智能科技有限公司 | 特定病毒的突變耐受表位的推估方法及系統 |
| WO2026013289A1 (en) * | 2024-07-12 | 2026-01-15 | Institut Pasteur | Measles-mumps-rubella (mmr) vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
| DK1375512T3 (da) | 2002-06-20 | 2009-10-26 | Pasteur Institut | Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger |
| DK1654370T3 (en) * | 2003-08-01 | 2018-08-20 | Government Of The Us Secretary Department Of Health And Human Services | ACCELERATED EBOLA VACCINATION |
| ES2423518T3 (es) | 2006-12-22 | 2013-09-20 | Institut Pasteur | Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada |
| EP2478103A4 (en) * | 2009-09-16 | 2014-02-19 | Univ Tulane | LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
| KR102314421B1 (ko) | 2011-07-11 | 2021-10-19 | 이노비오 파마수티컬즈, 인크. | 교차-보호성 아레나바이러스 백신 및 이의 사용 방법 |
| US11701418B2 (en) * | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP3103474A1 (en) * | 2015-06-12 | 2016-12-14 | Institut Pasteur | Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses |
-
2018
- 2018-12-20 AU AU2018392826A patent/AU2018392826B2/en active Active
- 2018-12-20 MX MX2020006476A patent/MX2020006476A/es unknown
- 2018-12-20 SG SG11202004899SA patent/SG11202004899SA/en unknown
- 2018-12-20 CA CA3085224A patent/CA3085224A1/en active Pending
- 2018-12-20 EP EP18857393.5A patent/EP3727411A2/en active Pending
- 2018-12-20 JP JP2020534373A patent/JP7841847B2/ja active Active
- 2018-12-20 WO PCT/IB2018/001620 patent/WO2019123018A2/en not_active Ceased
- 2018-12-20 US US16/954,592 patent/US11976305B2/en active Active
- 2018-12-20 CN CN201880082649.9A patent/CN111886342B/zh active Active
- 2018-12-20 KR KR1020207021052A patent/KR102822230B1/ko active Active
-
2020
- 2020-05-25 ZA ZA2020/03070A patent/ZA202003070B/en unknown
-
2023
- 2023-11-10 JP JP2023192505A patent/JP2024009058A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507707A5 (enExample) | ||
| RU2733834C1 (ru) | Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2 | |
| AU2001293222B2 (en) | Packaging of positive-strand RNA virus replicon particles | |
| CA2343653A1 (en) | Recombinant newcastle disease virus rna expression systems and vaccines | |
| JP2010530245A5 (enExample) | ||
| JP2017522907A5 (enExample) | ||
| EP2900687B1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| JP2018536433A5 (enExample) | ||
| JP2019530466A5 (enExample) | ||
| CN107921117A (zh) | Hpv疫苗 | |
| JP2017535267A5 (enExample) | ||
| JP2020524496A5 (enExample) | ||
| WO1997016539A1 (en) | Recombinant sendai virus | |
| JP2023523414A5 (enExample) | ||
| JP2004501646A5 (enExample) | ||
| IL275427B1 (en) | Hepatitis virus (HBV) vaccines and their uses | |
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| JP2023525785A (ja) | 安定化コロナウイルススパイクタンパク質をコードするｒｎａレプリコン | |
| JP2025169275A5 (enExample) | ||
| CA3205247A1 (en) | Rna construct | |
| CN101560520A (zh) | 乙脑/登革嵌合病毒及其应用 | |
| EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
| CN111218477A (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| JP2011507515A5 (enExample) | ||
| KR20160025553A (ko) | 세미-라이브 호흡기 세포융합 바이러스 백신 |